Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook

merck beat q1 estimates on strong keytruda sales and newer products. revenue came in at $16.29 billion, up 5% from a year ago and above the $15.82 billion analysts expected. adjusted loss per share was $1.28, better than the $1.51 loss forecast. keytruda sales hit $8.03 billion for the quarter, up 12% and above the $7.78 billion estimate. the injectable version launched last year brought in $128 million. newer lung drug winrevair generated $525 million, up 88% and above the $487 million forecast. the company narrowed its 2026 revenue outlook to $65.8-$67 billion and raised adjusted profit guidance to $5.04-$5.16 per share. merck swung to a net loss of $4.24 billion, driven by a $3.62 per share charge from its cidara therapeutics acquisition. gardasil sales fell 19% to $1.07 billion, with continued sluggish demand in china. animal health revenue rose 13% to $1.79 billion.